Search Result

Results for "

MC-38

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenosine Receptor (2) Akt (1) Antibody-Drug Conjugates (ADCs) (1) Apoptosis (4) ATM/ATR (1) Autophagy (3) Bacterial (1) c-Fms (1) C-type Lectin-like Receptors (CTLRs) (1) Calcium Channel (3) CTLA-4 (1) Cytochrome P450 (1) ERK (2) HDAC (3) IFNAR (2) IKZF Family (1) Indoleamine 2,3-Dioxygenase (IDO) (1) Integrin (1) Interleukin Related (3) Liposome (1) MAP4K (2) Microtubule/Tubulin (1) Molecular Glues (1) NF-κB (3) Orexin Receptor (OX Receptor) (1) PD-1/PD-L1 (4) Phosphatase (2) Potassium Channel (1) PROTACs (2) Ras (3) ROR (1) STAT (1) STING (5) TAM Receptor (1) TNF Receptor (3) Toll-like Receptor (TLR) (3) Transmembrane Glycoprotein (1)
By Research Areas:	Cancer (40) Cardiovascular Disease (5) Infection (4) Inflammation/Immunology (14)

By Targets:

Adenosine Receptor (2)

Akt (1)

Antibody-Drug Conjugates (ADCs) (1)

Apoptosis (4)

ATM/ATR (1)

Autophagy (3)

Bacterial (1)

c-Fms (1)

C-type Lectin-like Receptors (CTLRs) (1)

Calcium Channel (3)

CTLA-4 (1)

Cytochrome P450 (1)

ERK (2)

HDAC (3)

IFNAR (2)

IKZF Family (1)

Indoleamine 2,3-Dioxygenase (IDO) (1)

Integrin (1)

Interleukin Related (3)

Liposome (1)

MAP4K (2)

Microtubule/Tubulin (1)

Molecular Glues (1)

NF-κB (3)

Orexin Receptor (OX Receptor) (1)

PD-1/PD-L1 (4)

Phosphatase (2)

Potassium Channel (1)

PROTACs (2)

Ras (3)

ROR (1)

STAT (1)

STING (5)

TAM Receptor (1)

TNF Receptor (3)

Toll-like Receptor (TLR) (3)

Transmembrane Glycoprotein (1)

By Research Areas:

Cancer (40)

Cardiovascular Disease (5)

Infection (4)

Inflammation/Immunology (14)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Targets Recommended: CD38 p38 MAPK Melanocortin Receptor

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-128355A

(R)-IDO/TDO-IN-1	Indoleamine 2,3-Dioxygenase (IDO)	Others Cancer
(R)-IDO/TDO-IN-1 (compound 25) is an indoleamine-2,3-dioxygenase (IDO) inhibitor, with good pharmacokinetic properties. (R)-IDO/TDO-IN-1 exhibits anti-tumor activity in MC38 xenograft model. (R)-IDO/TDO-IN-1 shows synergistic effect with anti-PD-1 monoclonal antibody (SHR-1210) .

HY-168954

CSF1R-IN-26	c-Fms Apoptosis Akt ERK STAT	Inflammation/Immunology Cancer
CSF1R-IN-26 (Compound III-1) is the inhibitor for CSF-1R with an IC₅₀ of 20.07 nM. CSF1R-IN-26 promotes the polarization of M2 macrophages to M1 macrophages, thereby inducing apoptosis in MC-38 cancer cell. CSF1R-IN-26 inhibits the activation of AKT/ERK/STAT3 signaling pathway. CSF1R-IN-26 reconstructs the tumor immune microenvironment and exhibits antitumor activity in mouse models. CSF1R-IN-26 exhibits pharmacokinetics characteristics in SD rats with a half-life 1.86 hours, and an oral bioavailability of 79.22% .

HY-155491

Antibacterial agent 166	Bacterial	Cancer
Antibacterial agent 166 (Compound 19q), a derivative of Nitisinone (HY-B0607), is a selective and orally active *Fusobacterium nucleatum* inhibitor with a MIC₅₀ of 1 μg/mL. Antibacterial agent 166 effectively attenuates the migratory ability of MC-38 cells induced by Fusobacterium nucleatum. Antibacterial agent 166 is a promising anti-F. nucleatum lead compound and can be used for colorectal cancer (CRC) research .

HY-175361

RORγ agonist 2	ROR	Cancer
RORγ agonist 2 (Compound 34) is a selective RORγ agonist with an EC₅₀ of 0.03  μM for hRORγ. RORγ agonist 2 significantly inhibits tumors growth in syngeneic MC38 tumor mice model .

HY-161629

TLR8 agonist 7	Toll-like Receptor (TLR)	Cancer
TLR8 agonist 7 (Compound II-36) is an agonist for Toll-like receptor 8 (TLR8) with EC₅₀ <250 nM. TLR8 agonist 7 is stable in human and murine plasma, induces secretion of cytokines TNFα, with EC₅₀ <1 μM. TLR8 agonist 7 exhibits antitumor activity in MC38-HER2 xenograft mouse model with a tumor growth inhibition (TGI) rate of 98% .

HY-172930

PVTX-405	Molecular Glues IKZF Family Potassium Channel	Inflammation/Immunology Cancer
PVTX-405 is a selective and oral active IKZF2 molecular glue degrader with a DC₅₀ of 0.7 nM and a D_max of 91%. PVTX-405 enhances degradation efficiency, significantly reduces off-target degradation, and alleviates hERG inhibition with IC₅₀ of 48 µM. PVTX-405 significantly inhibits the growth of MC38 tumors, with greater synergistic anti-cancer efficacy in combination with immune checkpoint therapies (ICTs) (anti-PD1 or anti-LAG3) in the MC38 mouse tumor xenograft model using Crbn ^391V C57BL/6 mice .

HY-161630

TLR8 agonist 8	Toll-like Receptor (TLR)	Cancer
TLR8 agonist 8 (Compound II-72) is an agonist for Toll-like receptor 8 (TLR8) with EC₅₀ of 0.25-1 μM. TLR8 agonist 8 is stable in human and murine plasma, induces secretion of cytokines TNFα, with EC₅₀ <1 μM. TLR8 agonist 8 exhibits antitumor activity in MC38-HER2 xenograft mouse model with a tumor growth inhibition (TGI) rate of 89% .

HY-161631

TLR8 agonist 9	Toll-like Receptor (TLR)	Cancer
TLR8 agonist 9 (Compound II-77) is an agonist for Toll-like receptor 8 (TLR8) with EC₅₀ of 0.25-1 μM. TLR8 agonist 9 is stable in human and murine plasma, induces secretion of cytokines TNFα, with EC₅₀ <1 μM. TLR8 agonist 9 exhibits antitumor activity in MC38-HER2 xenograft mouse model with a tumor growth inhibition (TGI) rate of 97% .

HY-P991464

IBI37G5	TNF Receptor	Cancer
IBI37G5 is a human monoclonal antibody (mAb) targeting TNFRSF18/GITR/CD357. IBI37G5 has anti-tumor activity in MC38 and B16F10 mouse tumor models. IBI37G5 can be used in the study of cancer immunity .

HY-175487

A2AAR antagonist 4	Adenosine Receptor	Cancer
A2AAR antagonist 4 is an orally active A_2A Adenosine receptor antagonist with a K_i of 0.36 nM and a K_B of 1 nM at hA_2AAR. A2AAR antagonist 4 fully inhibits hA_2AAR and hA_2bAR at 10 μM. A2AAR antagonist 4 can be used for research of cancer, such as MC38 tiumor .

HY-P991528

PE0116	NF-κB	Inflammation/Immunology Cancer
PE0116 is a fully human CD137 agonistic monoclonal antibody generated from immunized harbor H2L2 human transgenic mice. PE0116 is a ligand block. PE0116 activates NF-κB signaling which significantly promotes T-cell proliferation and increases cytokine secretion in vitro. PE0116 exhibits robust antitumor activity in MC38 tumor model .

HY-175195

Adenosine receptor antagonist 6	Adenosine Receptor Interleukin Related IFNAR Cytochrome P450	Inflammation/Immunology Cancer
Adenosine receptor antagonist 6 is an orally active and selective A_2A adenosine receptor (A_2AAR) antagonist, with a K_i of 19.18 nM. Adenosine receptor antagonist 6 inhibits 5’-N-ethylcarboxamide adenosine (NECA) (HY-103173)-mediated cAMP production (IC₅₀ = 0.089 μM) and immunosuppression, while promoting IL-2 and IFN-γ secretion. Adenosine receptor antagonist 6 abolishes the immunosuppressive effects of adenosine on T-cell activation and cytokine release. Adenosine receptor antagonist 6 inhibits tumor growth in a CT26/MC38 xenograft model. Adenosine receptor antagonist 6 can be used for the study of colon cancer .

HY-174308

ZSA-215	STING	Inflammation/Immunology Cancer
ZSA-215 is a potent and orally active STING agonist with an EC₅₀ of 3.3 μM. ZSA-215 enhances STING signaling through promoting the phosphorylation of STING and interferon regulatory factor 3 (IRF3) and secretion of IFN-β. ZSA-215 inhibits tumor regression and long-term survival of mice in MC38 colon cancer model. ZSA-215 can be used to the study of colon cancerr .

HY-155740

PD-1/PD-L1-IN-32	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-32 (compound A56) is a potent PD-1/PD-L1 inhibitor (IC₅₀=2.4 nM), with anticancer activity. PD-1/PD-L1-IN-32 significantly inhibits tumor growth in hPD-L1 MC38 humanized mouse model, without obvious toxicity against mouse normal ability .

HY-162645

BPR5K230	TAM Receptor	Inflammation/Immunology Cancer
BPR5K230 is a dual inhibitor for the receptor tyrosine kinase MER and AXL, with IC₅₀ of 4.1 nM and 9.2 nM. BPR5K230 inhibits the proliferation of Ba/F3-MER with IC₅₀ of 5 nM. BPR5K230 exhibits good pharmacokinetic characteristics in mice, exhibits anti-inflammatory and antitumor against 4T1, MDA-MB-231, MC38 and Hepa1?6 in mouse models .

HY-138742

HPK1-IN-7	MAP4K	Cancer
HPK1-IN-7 is a potent, orally active HPK1 (hematopoietic progenitor kinase 1, MAP4K1) inhibitor (IC₅₀=2.6 nM) with excellent family and kinome selectivity. HPK1-IN-7 shows selectivity against IRAK4 (59 nM) and GLK (140 nM). HPK1-IN-7 shows robust efficacy against MC38 syngeneic tumor model in combination with anti-PD1 .

HY-149208

HDAC-IN-53	HDAC Apoptosis	Cancer
HDAC-IN-53 is an orally active, and selective HDAC1-3 inhibitor with IC₅₀ values of 47 nM, 125 nM, and 450 nM, respectively. HDAC-IN-53 does not inhibit class II HDACs (HDAC4, 5, 6, 7, 9; IC₅₀>10 μM). HDAC-IN-53 induces caspase-dependent apoptosis. HDAC-IN-53 significantly inhibits the growth of human tumor xenografts in nude mice and murine tumor growth in immune-competent mice bearing MC38 colon cancer .

HY-155848

LYP-IN-4	Phosphatase	Cancer
LYP-IN-4 (compound D14) is a reversible and selective inhibitor of lymphotyrosine phosphatase (LYP) (Ki=1.34 μM, IC50=3.52μM). LYP-IN-4 inhibits LYP to regulate TCR signaling, up-regulates PD-1/PD-L1 expression, and enhance anti-tumor immunity. LYP-IN-4 activates T cells and inhibits M2 macrophage polarization, inhibits tumor growth in MC38 isogenic mouse models.

HY-160421

TREM2-IN-1	Apoptosis	Inflammation/Immunology Cancer
TREM2-IN-1 (OPA) is a TREM2 inhibitor derived from oxaliplatin and artesunate. TREM2-IN-1 can relieves immunosuppressive tumor microenvironment and enhancing chemical anticancer efficiency. TREM2-IN-1 deters the tumor growth in mice models bearing MC38 colorectal tumor by reducing the number of CD206 ⁺ and CX₃CR1 ⁺ immunosuppressive macrophages. TREM2-IN-1 also promotes the expansion and infiltration of immunostimulatory dendritic, cytotoxic T and natural killer cells .

HY-P991613

BGB-A445	Orexin Receptor (OX Receptor) NF-κB	Cancer
BGB-A445 is a humanized non-ligand-blocking agonistic OX40 monoclonal antibody with high affinity to OX40. BGB-A445 activates downstream NF-κB pathway to induce immune cell activation, proliferation, and survival. BGB-A445 dose-dependently and significantly depletes regulatory T cells via antibody-dependent cellular cytotoxicity (ADCC). BGB-A445 demonstrates robust and dose-dependent antitumor efficacy in the MC38 mice models. BGB-A445 can be used for the researches of cancer, such as colon adenocarcinoma .

HY-P990117

Anti-Mouse/Rat/Human Osteopontin/SPP1 Antibody (MPIIIB10)	Integrin	Cardiovascular Disease Cancer
Anti-Mouse/Rat/Human Osteopontin/SPP1 Antibody (MPIIIB10) is a mouse-derived Osteopontin/SPP1 IgG1 κ type antibody inhibitor. Anti-Mouse/Rat/Human Osteopontin/SPP1 Antibody (MPIIIB10) blocks Angiotensin II (HY-13948)-induced DNA synthesis and collagen gel contraction in cardiac fibroblasts. Anti-Mouse/Rat/Human Osteopontin/SPP1 Antibody (MPIIIB10) significantly inhibits tumor growth in CT26 or MC38 tumors mice models .

HY-P991566

KD6001	CTLA-4	Cancer
KD6001 is a humanized IgG1κ monoclonal antibody, targeting CTLA4. KD6001 significantly disrupts CTLA-4 interactions with CD80 (IC₅₀: 16 ng/mL) and CD86. KD6001 enhances IL-2 and IFNγ expression in PHA-activated human lymphocytes and exhibits potent antitumor effects. KD6001 effectively inhibits tumor growth in MC38, B16, and Hepa1-6 tumor mice model. KD6001 can be used for cancers research, such as advanced melanoma, hepatocellular carcinoma and liver cancer .

HY-168081

PD-1/PD-L1-IN-52	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-52 (Compound III-5) is an orally active PD-1/PD-L1 inhibitor that blocks the interaction between PD-1 and PD-L1, with an IC₅₀ of 109.9 nM. PD-1/PD-L1-IN-52 exhibits antitumor activity in a C57BL/6 mouse xenograft model implanted with human PD-1-expressing MC38 colon cancer cells, with a TGI of 49.6% .

HY-B0984A

Fendiline 3 Publications Verification	Calcium Channel Ras STING Autophagy	Infection Cardiovascular Disease Cancer
Fendiline, a diphenylalkylamine type of antianginal agent, is an L-type calcium channel blocker (IC₅₀ of 17 µM). Fendiline is also a selective K-Ras inhibitor, and has no effect on H-Ras and N-Ras. Fendiline inhibits K-Ras plasma membrane localization (IC₅₀ of 9.64 μM), inhibits K-Ras signal output and blocks the proliferation of pancreatic, colon, lung, and endometrial cancer cell lines expressing oncogenic mutant K-Ras. Fendiline is a STING agonist and is able to inhibit the growth of multiple refractory cold tumors (MC38, CT26 and B16F10) .

HY-B0984

Fendiline hydrochloride 3 Publications Verification	Calcium Channel Ras STING Autophagy	Infection Cardiovascular Disease Cancer
Fendiline hydrochloride, a diphenylalkylamine type of antianginal agent, is an L-type calcium channel blocker (IC₅₀ of 17 µM). Fendiline hydrochloride is also a selective K-Ras inhibitor, and has no effect on H-Ras and N-Ras. Fendiline hydrochloride inhibits K-Ras plasma membrane localization (IC₅₀ of 9.64 μM), inhibits K-Ras signal output and blocks the proliferation of pancreatic, colon, lung, and endometrial cancer cell lines expressing oncogenic mutant K-Ras. Fendiline hydrochloride is a STING agonist and is able to inhibit the growth of multiple refractory cold tumors (MC38, CT26 and B16F10) .

HY-171572

Atezolizumab-MMAE	Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin Apoptosis	Inflammation/Immunology Cancer
Atezolizumab-MMAE is an anti-PD-L1 antibody-drug conjugate (ADC) with an EC₅₀ of 1.1 nM. Atezolizumab-MMAE is composed of a humanized anti-PD-L1 antibody (Atezolizumab) (HY-P9904), a lysosomally cleavable dipeptide linker (valine-citrulline), a tubulin inhibitor (MMAE) (HY-15162), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Atezolizumab-MMAE has a potent cytotoxicity (EC₅₀: 9.75-11.94 nM) and immune activation effect. Atezolizumab-MMAE has a significantly anti-tumor activity in MC38 xenograft PD-1-humanized immune system mice model .

HY-P990820

Anti-Mouse TIM-4 Antibody (RMT4-53)	Transmembrane Glycoprotein	Inflammation/Immunology Cancer
Anti-Mouse TIM-4 Antibody (RMT4-53) is a rat-derived IgG2b κ type antibody inhibitor, targeting to mouse TIM-4. Anti-Mouse TIM-4 Antibody (RMT4-53) can block T cell immunoglobulin and mucin domain 4 (TIM-4). Anti-Mouse TIM-4 Antibody (RMT4-53) can inhibit the engulfment of apoptotic cells and T cell proliferation. Anti-Mouse TIM-4 Antibody (RMT4-53) can be used for the researches of cancer, immunology and metabolic disease, such as MC38 tumor and graft .

HY-162972

PROTAC PD-L1 degrader-2	PROTACs PD-1/PD-L1	Cancer
PROTAC PD-L1 degrader-2 (Compound 9i) is a PROTAC degrader for PD-L1, that inhibits PD-L1 with an IC₅₀ of 197.4 nM and exhibits an affinity with PD-L1 with a K_d of 301 nM. PROTAC PD-L1 degrader-2 promotes the internalization of PD-L1 on the cell membrane, and induces PD-L1 degradation via the synergistic effect of the proteasome and lysosomal pathways. PROTAC PD-L1 degrader-2 can activate the immune system, and exhibits antitumor efficacy in MC38 C57BL/6 mouse model .

HY-B0984R

Fendiline hydrochloride (Standard)	Calcium Channel Ras STING Autophagy	Infection Cardiovascular Disease Cancer
Fendiline (hydrochloride) (Standard) is the analytical standard of Fendiline (hydrochloride). This product is intended for research and analytical applications. Fendiline hydrochloride, a diphenylalkylamine type of antianginal agent, is an L-type calcium channel blocker (IC50 of 17 µM). Fendiline hydrochloride is also a selective K-Ras inhibitor, and has no effect on H-Ras and N-Ras. Fendiline hydrochloride inhibits K-Ras plasma membrane localization (IC50 of 9.64 μM), inhibits K-Ras signal output and blocks the proliferation of pancreatic, colon, lung, and endometrial cancer cell lines expressing oncogenic mutant K-Ras. Fendiline hydrochloride is a STING agonist and is able to inhibit the growth of multiple refractory cold tumors (MC38, CT26 and B16F10) .

HY-153358

TNG260	HDAC	Cancer
TNG260 is a selective, orally effective inhibitor of HDAC1 and CoREST complex, with a 10-fold selectivity for HDAC1 over HDAC3 and a 500-fold selectivity for CoREST complex over NuRD and Sin3 complex. TNG260 reshapes the tumor immune microenvironment, reduces immunosuppressive neutrophil infiltration, promotes effector T cell recruitment, and reverses anti-PD-1 resistance caused by STK11 deficiency by inhibiting the activity of the CoREST-HDAC1 complex. TNG260 induces durable tumor regression in combination with α-PD1 in MC38 tumor-bearing mice with STK11 mutations, and has lower toxicity to bone marrow cells than non-selective HDAC inhibitors .

HY-P990304

Anti-Mouse 4-1BBL/CD137L Antibody (TKS-1)	TNF Receptor	Infection Inflammation/Immunology Cancer
Anti-Mouse 4-1BBL/CD137L Antibody (TKS-1) is a rat-derived IgG2a κ antibody inhibitor, targeting to mouse 4-1BBL/CD137L. Anti-Mouse 4-1BBL/CD137L Antibody (TKS-1) can block 4-1BB ligand (4-1BBL) and inhibit CD4 ⁺ and CD8 ⁺ T cells. Anti-Mouse 4-1BBL/CD137L Antibody (TKS-1) can be used for the researches of cancer, infection, inflammation and immunology, such as MC38 tumor, lymphocytic choriomeningitis virus (LCMV) infection and herpetic stromal keratitis (HSK) .

HY-175547

PROTAC HPK1 Degrader-5	PROTACs MAP4K ERK Interleukin Related IFNAR	Inflammation/Immunology Cancer
PROTAC HPK1 Degrader-5 is a potent and orally active HPK1 PROTAC degrader (DC₅₀ = 5.0 nM; D_max ≥ 99%). PROTAC HPK1 Degrader-5 significantly inhibits SLP76 phosphorylation and enhanced ERK pathway activation through degrading HPK1, thereby stimulating IL-2 and IFN-γ release. PROTAC HPK1 Degrader-5 exhibits the ability to overcome the immunosuppressive effects imposed by PGE2, NECA or TGF-β. PROTAC HPK1 Degrader-5 alone efficaciously inhibits tumor growth in an MC38 syngeneic mouse model. PROTAC HPK1 Degrader-5 can be used for the study of tumor (such as colorectal cancer) immunotherapy (Pink: Target protein ligand (HY-175549); Blue: E3 ligand (HY-W023573); Black: Linker; E3 ligand + Linker (HY-175551)) .

HY-169478

Lipid N2-3L	Liposome	Cancer
Lipid N2-3L is an ionizable cationic lipid (pK_a = 8.99) that can be used to generate supramolecular lipid nanoparticles (SMLNPs) for mRNA delivery. Lipid nanoparticles formed by encapsulating a luciferase reporter gene with Lipid N2-3L were detected to accumulate in the lymph nodes of mice, indicating that they can effectively enter the mouse immune system. Lipid nanoparticles formed by encapsulating ovalbumin mRNA and the TLR7/8 agonist Resiquimod (HY-13740) with Lipid N2-3L were able to reduce tumor volume and increase survival in the MC-38-OVA mouse colon cancer model. Lipid N2-3L can be used in the research of drug delivery for cancer-related therapies .

HY-153446

Tegeprotafib PTPN2/1-IN-1	Phosphatase	Cancer
Tegeprotafib (PTPN2/1-IN-1) (Compound 124) is an orally active PTPN1 and PTPN2 inhibitor with IC₅₀s of 4.4 nM and 1-10 nM against PTPN2 and PTP1B, respectively .

HY-P990179

Anti-Mouse NKG2AB6 Antibody (16A11)	C-type Lectin-like Receptors (CTLRs)	Inflammation/Immunology Cancer
Anti-Mouse NKG2AB6 Antibody (16A11) is an anti-mouse NKG2AB6 IgG2b monoclonal antibody. Anti-Mouse NKG2AB6 Antibody (16A11) reduces depletion of antigen-specific CD8 T cells. Anti-Mouse NKG2AB6 Antibody (16A11) can be used for research on cancer such as lung cancer and colon cancer .

HY-150617

Lartesertib M4076; ATM Inhibitor-5	ATM/ATR STING PD-1/PD-L1	Cardiovascular Disease Inflammation/Immunology Cancer
Lartesertib (M4076) is an inhibitor of the serine/threonine protein kinase ATM with high potency. Lartesertib can inhibit the growth of multiple hematopoietic cell lines. Additionally, when combined with the ATR inhibitor Tuvusertib (HY-111451), Lartesertib can promote the death of tumor cells, activate the immune signaling pathway, and exhibit anti-tumor activity .

HY-P990124

Anti-Mouse GITR Antibody (DTA-1)	TNF Receptor NF-κB Interleukin Related	Inflammation/Immunology Cancer
Anti-Mouse GITR Antibody (DTA-1) is a rat derived IgG2b monoclonal agonist antibody targeting mouse GITR. Anti-Mouse GITR Antibody (DTA-1) can activate T cells and B cells to enhance immune response. Anti-Mouse GITR Antibody (DTA-1) selectively enhances Th2 cell effector function through GITR signaling. Anti-Mouse GITR Antibody (DTA-1) may exacerbate allergic reactions. Anti-Mouse GITR Antibody (DTA-1) can be used for researches on cancer and allergic conditions such as colon cancer and allergic asthma. The recommed isotype control of Anti-Mouse GITR Antibody (DTA-1) is Rat IgG2b kappa, Isotype Control (HY-P990682) .

HY-154855

HDAC-IN-56	HDAC	Cancer
HDAC-IN-56 ((S)-17b) is an orally active class I histone deacetylase (HDAC) inhibitor with IC₅₀ values of 56.0 ± 6.0, 90.0 ± 5.9, 422.2 ± 105.1, >10000 nM for HDAC1, HDAC2, HDAC3, and HDAC4-11, respectively. HDAC-IN-56 has potent inhibitory activity while strongly increasing intracellular levels of acetylhistone H3 and P21 and effectively inducing G1 cell cycle arrest and apoptosis.HDAC-IN-56 has antitumor activity .

Cat. No.	Product Name	Target	Research Area

HY-P11060

MC38 SLP Adpgk Adpgk peptide	Peptides	Cancer
MC38 SLP Adpgk (Adpgk peptide) is a peptide neoantigen generated by mutation of the MC38 colon cancer cell line and can be used for the synthesis of nanoparticle vaccines .

HY-P11059

MC38 SLP Reps1 Reps1 peptide	Peptides	Cancer
MC38 SLP Reps1 is a peptide neoantigen generated by mutation of the MC38 colon cancer cell line and can be used for the synthesis of nanoparticle vaccines .

Cat. No.	Product Name	Target	Research Area